Immune Deficiency Clinical Research Studies
We are currently conducting immune deficiency studies. These studies research increasing the volume and flow rate of dosages for individuals with a primary immunodeficiency currently on Hizentra, with the hope that this new increased volume and flow rate helps individuals to lessen the amount of time spent receiving their medication. These medications are provided at absolutely no cost, with no insurance needed. You may also be reimbursed for your time and travel and will receive care from physicians affiliated with the Clinical Research Center of Alabama.
Modified Doses of Approved Subcutaneous Treatment
The study drug Cutaquig is approved by the FDA in adults for weekly administration and is currently sold commercially or primary immune deficiency. Cutaquig is not approved for use in children and is therefore considered to be an investigational product in this population. In addition, because of the 3 different dosing regiments, Cutaquig is considered investigational in this study. It is a human normal immunoglobulin for subcutaneous administration.